2.61

1.56% 0.04

After Hours: 2.66 0.05 +1.92%

Lipella Pharmaceuticals Inc (LIPO)

Overview News Price History Financials Discussions Forecast

Lipella Pharmaceuticals Inc stock is traded at $2.61, with a volume of 55,333. It is up +1.56% in the last 24 hours and up +8.30% over the past month. Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Previous Close:

$2.57

Open:

$2.6

24h Volume:

55,333

Relative Volume:

0.29

Market Cap:

$3.16M

Revenue:

Net Income/Loss:

$-4.74M

P/E Ratio:

-4.0303

EPS:

-0.6476

Net Cash Flow:

$-3.46M

1W Performance:

+2.76%

1M Performance:

+8.30%

6M Performance:

-49.34%

1Y Performance:

-67.38%

1-Day Range:

$2.57

$2.76

1-Week Range:

$2.53

$2.79

52-Week Range:

$2.21

$12.00

Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile

Name

Lipella Pharmaceuticals Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

412-901-0315

Address

400 N LEXINGTON ST, PITTSBURGH

Employee

Twitter

Next Earnings Date

Latest SEC Filings

LIPO's Discussions on Twitter

Compare LIPO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LIPO Lipella Pharmaceuticals Inc	2.61	3.16M	0	-4.74M	-3.46M	-0.75
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Lipella Pharmaceuticals Inc Stock (LIPO) Latest News

Dec 19, 2024

Lipella Pharmaceuticals Inc. announced that it has received $1.722 million in funding - Marketscreener.com

Dec 19, 2024

Dec 18, 2024

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement - The Manila Times

Dec 18, 2024

Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire

Dec 18, 2024

Dec 10, 2024

Lipella Pharmaceuticals Inc. announced that it expects to receive $6 million in funding - Marketscreener.com

Dec 10, 2024

Dec 06, 2024

Lipella Pharmaceuticals reschedules special meeting - Investing.com

Dec 06, 2024

Lipella Pharmaceuticals reschedules special meeting By Investing.com - Investing.com Canada

Dec 06, 2024

Dec 03, 2024

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus - GlobeNewswire

Dec 03, 2024

Lipella Pharmaceuticals Advances Novel Oral Treatment in Phase 2a Trial, Details Published in CUREUS - StockTitan

Dec 03, 2024

Nov 27, 2024

Hemorrhagic Cystitis Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail

Nov 27, 2024

Nov 24, 2024

Lipella Pharmaceuticals completes dosing for first cohort in LP-310 trial - MSN

Nov 24, 2024

Nov 21, 2024

Lipella Pharmaceuticals Announces Completion of First - GlobeNewswire

Nov 21, 2024

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group - GlobeNewswire

Nov 21, 2024

Lipella's LP-310 OLP Treatment Advances in Phase 2a Trial with Promising Safety Data | LIPO Stock News - StockTitan

Nov 21, 2024

Nov 20, 2024

Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges - MSN

Nov 20, 2024

Nov 17, 2024

Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023) - Yahoo Finance

Nov 17, 2024

Nov 15, 2024

LIPO stock touches 52-week low at $2.21 amid market challenges - Investing.com

Nov 15, 2024